The Gross-to-Net Trap

Why does a medication invented a century ago still carry a sticker price of hundreds of dollars per vial? In Part 2 of our series on prescription pricing, host Rachel Spahnn pulls back the curtain on Pharmacy Benefit Managers (PBMs)—the powerful, hidden corporate intermediaries operating between drug manufacturers and your local pharmacy counter.We trace how the "gross-to-net bubble" incentivizes artificially high list prices, explore how rebate games determine which drugs end up on health plan formularies, and examine the human cost through the tragic story of Alec Smith, a 26-year-old who aged off his mother's health insurance and died rationing insulin he could no longer afford.Key Takeaways & Concepts Covered The PBM Oligopoly: How three corporate entities (CVS Caremark, Express Scripts, and OptumRx) control roughly 80% of all prescription claims in the United States.The Gross-to-Net Bubble: The widening dollar gap between a drug's official "list price" (Wholesale Acquisition Cost) and the "net price" the drugmaker actually keeps after paying back rebates and fees to middlemen.Formulary Placement Mechanics: Why PBMs often prefer high-list-price, high-rebate drugs over lower-cost alternatives because their revenue share is tied to the total rebate size.The Out-of-Pocket Penalty: How patients in high-deductible health plans or without insurance pay coinsurance based on the inflated list price rather than the negotiated net price.Sources & Referenced ResearchJAMA Network / Health Affairs:Assessment of Commercial and Mandatory Discounts in the Gross-to-Net Bubble for Top Insulin Products (2023). Documenting the expansion of insulin rebates from $4.9 billion in 2012 to over $22 billion by 2019.Estimation of the Share of Net Expenditures on Insulin Captured by US Manufacturers, Wholesalers, Pharmacy Benefit Managers, and Pharmacies (2021). Showing that while manufacturer net revenues fell by ~31%, the share retained by PBMs and intermediaries rose dramatically.Drug Channels Institute (DCI):The Gross-to-Net Bubble Hits $356 Billion (Dr. Adam J. Fein, 2024–2026). Definitive reporting on the dollar gap between list prices and net realization across brand-name pharmaceuticals.Federal Trade Commission (FTC):Interim Staff Report on Pharmacy Benefit Managers: Prescription Drug Middlemen Impacting Cost and Access (2024). Examining market concentration, vertical integration, and formulary steering practices among major PBMs.KFF (Kaiser Family Foundation):Understanding the Role of Pharmacy Benefit Managers (PBMs) in Synthetic Drug Pricing and Patient Deductibles (2023/2024).Legislative & Historical Context:The Alec Smith Emergency Insulin Act (Minnesota, 2020): Passed in memory of Alec Smith to provide emergency, 30-day safety-net insulin access for uninsured and underinsured individuals.